

ASX Release

Placement and Share Purchase Plan announced on 15 November 2024 - Increase in Placement size

ADELAIDE, 15 November 2024: Anatara Lifesciences (ASX: ANR) ("**Anatara**" or "the **Company**") a developer of evidence-based solutions for gastrointestinal diseases in humans refers to its ASX Announcement released to the ASX earlier today, on 15 November 2024 (**Earlier Announcement**).

Anatara confirms that it has increased the size of the Placement by \$90,000, taking the Placement from \$0.66m to \$0.75m. As such, it is proposed that Anatara will now issue a total of 15,000,000 ordinary shares (**Placement Shares**) at \$0.05 per share to new and existing sophisticated and institutional investors.

The Placement Shares will be issued within Anatara's 15% placement capacity under ASX Listing Rule 7.1. The Placement Shares will rank equally with existing fully paid shares in Anatara. No Placement Shares will be issued to a related party or otherwise to any person referred to in Listing Rule 10.11.

The information relating to the Share Purchase Plan, the timetable and the use of funds as disclosed in the Earlier Announcement have not changed.

This Announcement has been authorised for release by the Anatara Board.

For more information please contact:

Dr. David Brookes
Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

Dirk van Dissel
Candour Advisory – Investor Relations
+61 (0) 408 326 367
dirk@candouradvisory.com.au

About GaRP

Anatara's GaRP product is a multi-component, multi-coated complementary medicine designed to address underlying factors associated with chronic gastrointestinal conditions such as IBS and IBD. GaRP is the working name for the product from the Company's Gastrointestinal ReProgramming project that was designed to assist restoration and maintenance of the gastrointestinal tract (GIT) lining as a barrier and assist the homeostasis of the microbiome. The product is made of GRAS (Generally Regarded As Safe) components.



About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.



Registered Office
C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000
Email info@anatara.com | Website anataralifesciences.com

